Erik Ramon-Gil

6PUBLICATIONS

64CO-AUTHORS

Haematological tumoursCancer cell biologyCancer diagnosisMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jul 13, 2026

Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma.

|Mar 11, 2026

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Bruno Beernaert, Rose L Jady-Clark, Parin Shah

|May 16, 2025

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening.

Amy L Collins, Keara Kirkness, Erik Ramon-Gil

|Mar 06, 2024

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

Rebecca Garnham, Daniel Geh, Ryan Nelson

|Aug 03, 2023

Harnessing neutrophil plasticity for HCC immunotherapy.

Erik Ramon-Gil, Daniel Geh, Jack Leslie

|Jun 22, 2021

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Laura Torrens, Carla Montironi, Marc Puigvehí

Pageof 1

Frequent Collaborators

Jack Leslie

Derek A Mann

Daniel Geh

Josep M Llovet

Rch Man

R Savoldelli

Eileen E Parkes

C Schmidl

A H de Sande

J Torres-Yaguana

Frequent Collaborators

Jack Leslie

Derek A Mann

Daniel Geh

Josep M Llovet